Daratumumab-containing* regimens are recommended as treatment options by the National Comprehensive Cancer Network® (NCCN®)

For patients with newly diagnosed multiple myeloma

NCCN preferred regimens

Daratumumab, lenalidomide, and dexamethasone (Category 1) primary therapy for non-transplant candidates

NCCN other recommended regimens

Daratumumab, bortezomib, melphalan, and prednisone (Category 1) primary therapy for non-transplant candidates

NCCN useful in certain circumstances

Daratumumab, bortezomib, thalidomide, and dexamethasone (Category 2A) primary therapy for transplant candidates

For patients with previously treated multiple myeloma

NCCN preferred regimens

Daratumumab, lenalidomide, and dexamethasone (Category 1) for previously treated multiple myeloma

Daratumumab, bortezomib, and dexamethasone (Category 1) for previously treated multiple myeloma

Daratumumab, carfilzomib, and dexamethasone (Category 1) for previously treated multiple myeloma

Useful in certain circumstances

Daratumumab (Category 2A) for previously treated multiple myeloma

Category 1=based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A=based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

*Daratumumab includes daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection and daratumumab (DARZALEX®) for intravenous infusion. Daratumumab and hyaluronidase-fihj for subcutaneous injection has different dosing and administration instructions compared to daratumumab for intravenous infusion.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma V7.2021. © National Comprehensive Cancer Network, Inc. 2021. Accessed May 2, 2021. All rights reserved. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

See nccn.org for definitions of NCCN Categories of Preference.